SANDOZ BRIMONIDINE / TIMOLOL DIN 02374331
Health Canada record
| Active ingredient(s) | BRIMONIDINE TARTRATE 0.2 %; TIMOLOL (TIMOLOL MALEATE) 0.5 % |
|---|---|
| Dosage form | Solution |
| Route | Ophthalmic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S01ED51 TIMOLOL, COMBINATIONS |
| Original market date | |
| Current status date | 31-Jul-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BRIMONIDINE TARTRATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02236876 | ALPHAGAN | ABBVIE CORPORATION | Solution | BRIMONIDINE TARTRATE 0.2 % | Marketed |
| 02248151 | ALPHAGAN P | ABBVIE CORPORATION | Solution | BRIMONIDINE TARTRATE 0.15 % | Marketed |
| 02375311 | APO-BRIMONIDINE-TIMOP | APOTEX INC | Solution | BRIMONIDINE TARTRATE 0.2 %; TIMOLOL (TIMOLOL MALEATE) 0.5 % | Marketed |
| 02562316 | BRIMONIDINE | STERI-MED PHARMA INC. | Solution | BRIMONIDINE TARTRATE 0.2 % | Marketed |
| 02540673 | BRIMONIDINE | MICRO LABS LIMITED | Solution | BRIMONIDINE TARTRATE 0.2 % | Approved |
| 02301334 | BRIMONIDINE P | AA PHARMA INC | Solution | BRIMONIDINE TARTRATE 0.15 % | Marketed |
| 02570769 | BRIMONIDINE-TIMOLOL | MICRO LABS LIMITED | Solution | BRIMONIDINE TARTRATE 0.2 %; TIMOLOL (TIMOLOL MALEATE) 0.5 % | Approved |
| 02248347 | COMBIGAN | ABBVIE CORPORATION | Solution | BRIMONIDINE TARTRATE 0.2 %; TIMOLOL (TIMOLOL MALEATE) 0.5 % | Marketed |
| 02449226 | JAMP BRIMONIDINE | JAMP PHARMA CORPORATION | Solution | BRIMONIDINE TARTRATE 0.2 % | Marketed |
| 02531704 | JAMP BRIMONIDINE/TIMOLOL | JAMP PHARMA CORPORATION | Solution | BRIMONIDINE TARTRATE 0.2 %; TIMOLOL (TIMOLOL MALEATE) 0.5 % | Marketed |
| 02517698 | LUMIFY | BAUSCH & LOMB INC | Solution | BRIMONIDINE TARTRATE 0.025 % | Marketed |
| 02507811 | MED-BRIMONIDINE | GENERIC MEDICAL PARTNERS INC | Solution | BRIMONIDINE TARTRATE 0.2 % | Marketed |
| 02515350 | RIVA-BRIMONIDINE | LABORATOIRE RIVA INC. | Solution | BRIMONIDINE TARTRATE 0.2 % | Marketed |
| 02305429 | SANDOZ BRIMONIDINE | SANDOZ CANADA INCORPORATED | Solution | BRIMONIDINE TARTRATE 0.2 % | Marketed |
| 02260077 | APO-BRIMONIDINE | APOTEX INC | Solution | BRIMONIDINE TARTRATE 0.2 % | Dormant |
| 02249456 | BRIMONIDINE | PHARMASCIENCE INC | Solution | BRIMONIDINE TARTRATE 0.2 % | Cancelled Pre Market |
| 02246283 | BRIMONIDINE OPHTHALMIC | PHARMEL INC | Solution | BRIMONIDINE TARTRATE 0.2 % | Cancelled Pre Market |
| 02515377 | BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION | HIKMA CANADA LIMITED | Solution | BRIMONIDINE TARTRATE 0.2 % | Cancelled Post Market |
| 02245942 | BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION 0.2% | ALCON CANADA INC | Solution | BRIMONIDINE TARTRATE 0.2 % | Cancelled Pre Market |
| 02246285 | DOM-BRIMONIDINE | DOMINION PHARMACAL | Solution | BRIMONIDINE TARTRATE 0.2 % | Cancelled Pre Market |
| 02246284 | PMS-BRIMONIDINE | PHARMASCIENCE INC | Solution | BRIMONIDINE TARTRATE 0.2 % | Cancelled Post Market |
| 02243026 | RATIO-BRIMONIDINE | TEVA CANADA LIMITED | Solution | BRIMONIDINE TARTRATE 0.2 % | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 31631 | 2023-09-15 | Abbreviated New Drug Submission (ANDS) |
International API supply for BRIMONIDINE TARTRATE
11 valid EDQM Certificates of Suitability from 11 holders. 12 active FDA Drug Master Files.
Request a quote for SANDOZ BRIMONIDINE / TIMOLOL